Clinical trial Recruiting at 2 sites Phase2; Phase3 Interventional Ages 1 Day to 14 Days

High-intensity and cycled phototherapy for newborn jaundice

Official title: Neonatal Hyperbilirubinemia - Phototherapeutic Treatment Strategies

Run by Regionshospital Nordjylland · NCT06702241 · Data updated 2026-11-12

This test compares higher-intensity and intermittent (cycled) phototherapy to standard continuous light to see which lowers bilirubin faster in newborns born at or after 33 weeks with non-hemolytic jaundice.

More Neonatal Hyperbilirubinemia trials

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages1 Day to 14 Days
SexAll
Enrollment116 (estimated)
SponsorRegionshospital Nordjylland
Government
Locations2 sites (Aalborg and 1 other locations)
StatusRecruiting
StartedJanuary 14, 2025
Main results expectedNovember 1, 2027
Study endsNovember 1, 2029
Registry record updatedNovember 20, 2025
Trial IDNCT06702241 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Newborns born at ≥33+0 weeks, weighing ≥1800 g, with serum bilirubin above the national treatment threshold and without signs of hemolysis or rapidly rising bilirubin are eligible.

Probably not a fit

Infants with jaundice within the first 24 hours of life, rapidly rising bilirubin suggestive of hemolysis, or those needing exchange transfusion or multi-sided intensive therapy are unlikely to benefit from the interventions tested here.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized multicenter trial will enroll 116 newborns (≥33+0 weeks gestation, ≥1800 g) with non-hemolytic hyperbilirubinemia above Danish treatment thresholds. All infants receive 12 hours of combined overhead phototherapy plus a biliblanket, with overhead irradiance set to 40, 55, or 70 µW/cm²/nm; the 70 µW/cm²/nm arm is split into continuous and cycled (intermittent) treatment, creating four groups. The trial is powered to compare bilirubin response across irradiance levels to define an upper effective limit and to compare cycled versus continuous delivery. Infants with rapidly rising bilirubin or other indications for immediate intensified therapy (multi-sided lights, exchange transfusion, or immunoglobulin) are excluded.

Why it matters

Potential benefit: If successful, the results could identify an optimal phototherapy dose and show whether intermittent treatment is as effective as continuous light, potentially shortening treatment or improving comfort.

How similar studies have gone: Smaller prior studies suggest cycled phototherapy can be as effective as continuous treatment, but evidence on benefits of very high irradiance levels remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Hyperbilirubinemia with a total serum bilirubin level above the limit of necessary treatment according to the Danish Pediatric Society's guidelines
* Birth weight \>1800g
* Gestational age \>33+0

Exclusion Criteria:

* Hyperbilirubinemia within the first 24 hours of life
* Rapidly increasing serum levels of bilirubnemia indicating pathology or hemolysis

Where it's running

  • Aalborg University Hospital, The Neonatal Department
    Aalborg, Denmark
    Recruiting
  • The North Denmark Regional Hospital, The Pediatric Department
    Hjørring, Denmark
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.